Tiziana Life Sciences’ Post

I have been given the amazing opportunity, with the support of the Bellarmine College of Liberal Arts, the ACE program at LMU and the PRRISM lab, to present my poster at the Society of Behavioral Medicine (SBM) conference in Philadelphia. My poster presentation was on the secondary analysis that I conducted on the HINTS data which looked into the association between cancer risk perception and cigarette health warning labels. #sbm #hints

Join me learning more from James on Perlecan in Cardiomyocyte development, and how he utilized the #denovoMATRIX to understand the role of the ECM in that.

Age-Related Macular Degeneration (AMD) affects millions worldwide, but the future is looking brighter thanks to Espansione Group's LightWave I clinical trial. 🚀 This first multicentric study focuses on patients with grade 2-3 AMD and employs photobiomodulation (Light Modulation® Low-Level Light Therapy (LM® LLLT)) to slow disease progression. Dr. Claudio Iovino and Dr. Enrico Borrelli, two of our esteemed investigators, are excited about the potential impact on patient care and healthcare economics. Discover the astonishing results of this groundbreaking research here: https://lnkd.in/dVENsjUM #espansionegroup #scienceonward #dryamd #geographicatrophy #photobiomodulation #PBM

Just hours ago, a paper detailing the two-year follow-up results of our Phase 1 clinical trial featuring CYP-001, our innovative Cymerus™ off-the-shelf iPSC-derived MSC product, was published in the prestigious Nature Medicine journal. This is the second paper published in Nature Medicine regarding this trial which reports survival rate compares very favourably to previously reported outcomes in SR-aGvHD - 60% vs. historical prognosis of below 20% two-year overall survival rate. “The publication of a second paper on this trial in such a high-impact journal is a testament to the importance of this project to the wider field of cellular therapy,” John Rasko AO, the international coordinating Principal Investigator for the trial. Read the full announcement here: https://bit.ly/3IhTz71 #stemcells #innovation #aGvHD #NatureMedicine #newsalert

A great summary of what we are trying to achieve.

Exciting news! In cooperation with the ICRS, I am thrilled to watch the new interesting scientific series „The wonderful World of Cartilage Restoration and Joint Preservation“ This series covers a wide range of cartilage topics, for scientists, clinical researchers and physicians. ICRS - International Cartilage Regeneration & Joint Preservation Society #Arthroskopie #Knorpel #Knie #Sportmedizin

#DidYouKnow? In July 1921: An Historical Day in Diabetes Treatment! 🌟 In July 1921, Dr. Frederick Banting and Charles Best achieved a groundbreaking milestone in medical history at the University of Toronto, Canada. They successfully isolated insulin for the first time, revolutionizing #diabetes treatment forever. Dr. Banting, a surgeon, and Best, a medical student, conducted pioneering research on dogs, demonstrating that insulin injections could normalize blood glucose levels in animals with induced diabetes symptoms. This pivotal discovery laid the foundation for insulin therapy in humans. Just months later, on January 11th, 1922, 14-year-old Leonard Thompson became the first person to receive insulin treatment. This marked a monumental shift, turning diabetes from a fatal illness into a manageable condition. The impact of Banting and Best's work was profound and far-reaching. By 1923, insulin was being produced on a large scale, saving countless lives worldwide. Their efforts were duly recognized when Dr. Banting and Professor John Macleod received the #NobelPrize in Medicine in 1923. Though Charles Best, who played a crucial role, was not initially included, Banting ensured recognition by sharing the award money with him. Today, their legacy lives on as insulin remains a cornerstone of diabetes treatment, showcasing the power of collaborative research and dedication to improving healthcare globally. #MedicalHistory #DiabetesTreatment #CytoSorbents #ScienceFacts

Today is the 9th Annual World FSHD Day, a significant moment to raise awareness about Facioscapulohumeral Muscular Dystrophy (FSHD). FSHD is a complex and challenging condition that most commonly affects the muscles of the face, shoulders, and upper arms. TRiNDS is dedicated to advancing research and finding innovative treatments for FSHD. Join us in our mission to improve the lives of those affected by FSHD. Visit our website at www.TrindsTRiNDS.com to learn more about our groundbreaking work, upcoming clinical trials, and how you can get involved in making a difference. #FSHDDay #ClinicalResearchOrganization #ClinicalTrials #DuchenneAwareness #MuscularDystrophy #MuscularDystrophyResearch #RareDiseaseResearch #ResearchForACure #PatientDrivenResearch

Innovative research on age-related macular degeneration.

Our Latest Manuscript is Now Live! 📚 I am delighted to announce the publication of our original manuscript titled "Face-to-face and telerehabilitation delivery of circuit training have similar benefits and acceptability in patients with knee osteoarthritis: a randomised trial". In this groundbreaking study, we explored the effectiveness of telerehabilitation in delivering a periodized circuit training program for adults with knee osteoarthritis. Our findings reveal that telerehabilitation is non-inferior to face-to-face care in improving pain intensity and physical function. But that's not all – we also delved into clinical and morphological characteristics to uncover comprehensive insights. Read the full article here: https://lnkd.in/d5R63iUf 📖 #ClinicalResearch #Telerehabilitation #KneeOsteoarthritis #HealthcareInnovation Ricardo Ferrari, Stela Mattiello, Marcos de Noronha, Daniel White.